PDS Biotechnology (NASDAQ:PDSB) reported a smaller first-quarter loss and highlighted changes to its late-stage head and neck cancer trial that management said could shorten development timelines and reduce costs.
On the company’s first quarter 2026 earnings call, Chief Executive Officer Dr. Frank Bedu-Addo said the company’s “major focus was on advancing our clinical programs,” and that PDS made “significant progress” during the quarter. Chief Medical Officer Dr. Kirk Shepard detailed updates across the company’s oncology pipeline, while Chief Financial Officer Lars Boesgaard reviewed financial results for the quarter ended March 31, 2026.
